# HLX43

Source: https://onco.cc/drugs/hlx43/  
OnCo record `hlx43` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HLX43 is an experimental antibody-drug conjugate from Shanghai Henlius Biotech in phase 3 trials for non-small-cell lung cancer, cervical cancer and ovarian cancer, aimed at PD-L1 and EGFR.

## Summary

HLX43 is an antibody-drug conjugate developed by Shanghai Henlius Biotech. Its targets are PD-L1 and EGFR (the sponsor names PD-L1). The sponsor states: HLX43 is an anti-PD-L1 antibody-drug conjugate (ADC), studied as monotherapy or combined with the anti-EGFR antibody HLX07. ClinicalTrials.gov describes the intervention as: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07459751 (A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer, cervical cancer, ovarian cancer and oesophageal cancer. The largest, NCT07459751, plans to enrol 706 participants with primary completion expected 2030-01-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: HLX43 is an anti-PD-L1 antibody-drug conjugate (ADC), studied as monotherapy or combined with the anti-EGFR antibody HLX07.

## Sources

- ClinicalTrials.gov: trials of HLX43: https://clinicaltrials.gov/search?intr=HLX43

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)
- trials: [A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07459751/), [A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy](https://onco.cc/trials/nct06769113/), [A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors](https://onco.cc/trials/nct06769152/)

---
JSON: https://onco.cc/api/v1/entities/hlx43.json